SCHEMBL16286148

SCHEMBL16286148

O=c1c(-c2ccccc2)cc2ccc(Nc3ccc(N4CCNCC4)cc3)cc2n1Cc1ccccc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 3/20 0.42
C5AR1 P21730 1/20 0.41
LYN P07948 2/20 0.40
SRC P12931 2/20 0.40
EGFR P00533 1/20 0.39
BTK Q06187 1/20 0.39
CDK4 P11802 2/20 0.38
CCND1 P24385 2/20 0.38
CCND2 P30279 1/20 0.38
CCND3 P30281 1/20 0.38
KDM1A O60341 1/20 0.37
BRD4 O60885 1/20 0.37
STAT6 P42226 1/20 0.36
GAA P10253 1/20 0.36
KIF11 P52732 2/20 0.36
GUSB P08236 1/20 0.36
ACVR1 Q04771 2/20 0.36
ACVR1B P36896 1/20 0.36
TGFBR1 P36897 1/20 0.36
ACVRL1 P37023 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16286147 0.90 BTK (0.50) PTK2C5AR1LYNSRCBTK
SCHEMBL16285686 0.87 LYN (0.46) LYNSRCBTKCDK4CCND1
SCHEMBL16286112 0.86 PTK2 (0.45) PTK2C5AR1EGFRCDK4CCND1
SCHEMBL10192792 0.83 CDK4 (0.51) PTK2EGFRCDK4CCND1CCND2
SCHEMBL16286149 0.82 IDH2 (0.38) PTK2KIF11
SCHEMBL16285680 0.78 BTK (0.55) LYNSRCEGFRBTKCDK4
SCHEMBL16286126 0.76 CDK4 (0.44) PTK2C5AR1SRCEGFRBTK
SCHEMBL16286129 0.75 TDP1 (0.40) PTK2C5AR1CDK4CCND1GAA
SCHEMBL10192791 0.74 WEE1 (0.58) PTK2SRCBTKCDK4CCND1
SCHEMBL16285663 0.72 CDK4 (0.42) CDK4CCND1CCND2CCND3KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140364430-A1 METHODS FOR TREATING SCHIZOPHRENIA AFRAXIS HOLDINGS INC (US) 2014-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140364430-A1 METHODS FOR TREATING SCHIZOPHRENIA GRIN2A, GRIN2C, GRIN3A PTK2 476/4885C5AR1 4677/4885LYN 1996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.